BNP/PUT/CARL ZEISS MEDITEC/100/0.1/20.12.24 Stock

Warrant

DE000PN4Y6S2

Delayed Deutsche Boerse AG 11:20:44 2024-06-28 EDT
3.39 EUR +4.31% Intraday chart for BNP/PUT/CARL ZEISS MEDITEC/100/0.1/20.12.24
Current month+80.56%
1 month+133.81%
Date Price Change
24-06-28 3.39 +4.31%
24-06-27 3.25 +2.85%
24-06-26 3.16 -6.78%
24-06-25 3.39 +3.04%
24-06-24 3.29 -7.06%

Delayed Quote Deutsche Boerse AG

Last update June 28, 2024 at 11:20 am

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying CARL ZEISS MEDITEC AG
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PN4Y6S
ISINDE000PN4Y6S2
Date issued 2023-06-20
Strike 100
Maturity 2024-12-20 (175 Days)
Parity 10 : 1
Emission price 1.1
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 3.66
Lowest since issue 0.55
Delta-0.83x
Omega 1.591
Premium0.08x
Gearing1.91x
Moneyness 1.523
Difference Strike 34.35
Difference Strike %+34.35%
Spread 0.04
Spread %1.16%
Intrinsic value 3.435

Company Profile

Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.
Sector
-
More about the company

Ratings for Carl Zeiss Meditec AG

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Carl Zeiss Meditec AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
67.4 EUR
Average target price
82 EUR
Spread / Average Target
+21.66%
Consensus